Scholar Rock (SRRK) PT Raised to $33 at Wedbush, After Company Releases Clinical Trial Data
Wedbush analyst David Nierengarten raised ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
